Original Article
Amiodarone to Prevent Recurrence of Atrial Fibrillation
N Engl J Med 2000; 342:913-920March 30, 2000
- Abstract
Background
The restoration and maintenance of sinus rhythm is a desirable goal in patients with atrial fibrillation, because the prevention of recurrences can improve cardiac function and relieve symptoms. Uncontrolled studies have suggested that amiodarone in low doses may be more effective and safer than other agents in preventing recurrence, but this agent has not been tested in a large, randomized trial.
Methods
We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone. We randomly assigned patients who had had at least one episode of atrial fibrillation within the previous six months to amiodarone or to sotalol or propafenone, given in an open-label fashion. The patients in the group assigned to sotalol or propafenone underwent a second randomization to determine whether they would receive sotalol or propafenone first; if the first drug was unsuccessful the second agent was prescribed. Loading doses of the drugs were administered and electrical cardioversion was performed (if necessary) within 21 days after randomization for all patients in both groups. The follow-up period began 21 days after randomization. The primary end point was the length of time to a first recurrence of atrial fibrillation.
Results
Of the 403 patients in the study, 201 were assigned to amiodarone and 202 to either sotalol (101 patients) or propafenone (101 patients). After a mean of 16 months of follow-up, 71 of the patients who were assigned to amiodarone (35 percent) and 127 of those who were assigned to sotalol or propafenone (63 percent) had a recurrence of atrial fibrillation (P<0.001). Adverse events requiring the discontinuation of drug therapy occurred in 18 percent of the patients receiving amiodarone, as compared with 11 percent of those treated with sotalol or propafenone (P=0.06).
Conclusions
Amiodarone is more effective than sotalol or propafenone for the prevention of recurrences of atrial fibrillation.
Media in This Article
Figure 2
Hazard Ratios and 95 Percent Confidence Intervals for the Recurrence of Atrial Fibrillation in the Amiodarone Group as Compared with the Group Assigned to Sotalol or Propafenone.Figure 1
Kaplan–Meier Estimates of the Percentage of Patients Remaining Free of Recurrence of Atrial Fibrillation.Article Activity
- Article
Atrial fibrillation is the most common arrhythmia requiring treatment and affects 5 percent of people older than 65 years.1,2 The number of hospital admissions for atrial fibrillation in the United States more than doubled from 1984 to 1994, from 111,000 to 270,000.3 These numbers are probably underestimates, because many episodes of atrial fibrillation are treated on an outpatient basis or in emergency rooms, and admissions for complications such as stroke and heart failure are not necessarily attributed to atrial fibrillation.
There are multiple clinical consequences of atrial fibrillation. Patients often have disabling palpitations. In addition, the loss of effective atrial contraction may result in impaired cardiac performance, even after control of the ventricular response rate is achieved; such impairment can lead to reduced exercise tolerance and, in some patients, to congestive heart failure.4-7 Atrial fibrillation is associated with a quintupling of the risk of stroke in patients who are not receiving anticoagulant therapy and a doubling of the rate of death in all patients.1,8-10
To control symptoms, improve functional capacity, and reduce the risk of embolism, it is common practice to restore sinus rhythm; however, atrial fibrillation recurs within three to six months in at least one half of treated patients.8,11-22 The long-term use of quinidine and other class I agents for the treatment of atrial fibrillation has recently been questioned, because retrospective analyses have suggested that such agents may increase mortality.11,23 Concern about proarrhythmic effects is particularly pertinent for patients with atrial fibrillation since, by itself, atrial fibrillation is rarely fatal.
Data from several nonrandomized trials and two small, randomized trials have suggested that low-dose amiodarone may be more effective than other antiarrhythmic agents in treating atrial fibrillation22,24-29; however, the limited available results are not conclusive. We conducted a large, prospective, nonblinded, randomized trial to test the hypothesis that low-dose amiodarone is more efficacious in preventing recurrences of atrial fibrillation than antiarrhythmic therapy with sotalol or propafenone.
Methods
Study Design
The details of the protocol have been published previously.30 The Canadian Trial of Atrial Fibrillation was conducted in 19 cardiology centers throughout Canada. The investigational review board of each institution approved the study, and all patients gave written informed consent. Recruitment began in November 1996, randomization was concluded in February 1998, and follow-up was terminated in February 1999.
Inclusion Criteria
To be eligible, patients had to have had an episode of symptomatic atrial fibrillation within the preceding six months for which long-term antiarrhythmic drug therapy was planned. At least one episode of atrial fibrillation had to have lasted more than 10 minutes (determined by history taking), and electrocardiographic confirmation was required. This criterion was chosen arbitrarily in an attempt to prevent the enrollment of patients with clinically inconsequential atrial tachyarrhythmias.
Exclusion Criteria
The exclusion criteria were as follows: atrial fibrillation known to have been present continuously for more than 6 months, myocardial infarction during the previous 6 months, cardiac surgery during the previous 30 days, moderate or severe cardiac disability (New York Heart Association functional class III or IV), atrial fibrillation associated with an acute reversible condition, a serum creatinine concentration of more than 2.8 mg per deciliter (250 μmol per liter), a serum alanine aminotransferase concentration more than 2.5 times the upper limit of normal, chronic lung disease requiring bronchodilator therapy, the Wolff–Parkinson–White syndrome, previous long-term therapy (lasting 4 weeks or more) or intolerance of study drugs, untreated hypothyroidism, a corrected QT interval of more than 480 msec or an uncorrected QT interval of more than 500 msec in the absence of bundle-branch block, bradycardia (defined as a heart rate of less than 50 beats per minute for a period of more than one minute while the patient was awake), second-degree or third-degree atrioventricular block or a sinus pause of more than two seconds without a permanent pacemaker, an age of less than 18 years, a need for antiarrhythmic therapy for arrhythmias other than atrial fibrillation, and any medical condition that would make survival for 1 year unlikely. In addition, premenopausal women who had not undergone tubal ligation or hysterectomy were excluded.
Randomization, Therapy, and Follow-up
Patients with atrial fibrillation lasting more than 48 hours had to undergo treatment with an anticoagulant agent at a dosage adjusted to achieve an international normalized ratio of 2 or more for a minimum of three weeks before randomization.31 After written informed consent was obtained, patients were randomly assigned to receive amiodarone or to receive sotalol or propafenone, in an open-label fashion. The patients assigned to sotalol or propafenone underwent a second randomization to determine whether they would receive sotalol or propafenone first. Loading doses of the drugs were administered and electrical cardioversion, if necessary, was performed within 21 days after randomization for the patients in both groups. Cardioversion was recommended if atrial fibrillation persisted after 14 days of loading doses of amiodarone and after 4 days of treatment with either sotalol or propafenone. If the first drug administered to a patient assigned to sotalol or propafenone was unsuccessful, the second agent was prescribed and cardioversion was reattempted. An electrocardiogram was transmitted by telephone on days 7 and 14, and patients were reevaluated in the clinic 21 days after randomization.
Amiodarone was given at a dose of 10 mg per kilogram of body weight each day for 14 days, followed by 300 mg per day for 4 weeks, after which a daily maintenance dose of 200 mg was given. Sotalol was administered as follows: 160 mg every 12 hours to men 70 years of age or younger who had a creatinine concentration of 1.5 mg per deciliter (130 μmol per liter) or less and who weighed at least 70 kg; 80 mg every 8 hours to men who were older than 70, men who had a creatinine concentration of more than 1.5 mg per deciliter, men who weighed less than 70 kg, and to women 70 or younger who had a creatinine concentration of 1.2 mg per deciliter (110 μmol per liter) or less; and 80 mg every 12 hours to women who were older than 70 or who had a creatinine concentration of more than 1.2 mg per deciliter. Propafenone was given at a dose of 300 mg every 12 hours or 150 mg every 6 hours to patients who were 70 years of age or younger and who weighed at least 70 kg; a dose of 150 mg every 8 hours was given to patients older than 70 or those who weighed less than 70 kg.
Patients were assessed by a nurse coordinator and a physician at three months and every six months thereafter. The minimal duration of follow-up was one year. Twelve-lead electrocardiograms were obtained at each visit. Chest x-ray films were obtained at 6, 12, and 24 months, and measurements of thyrotropin and alanine aminotransferase were obtained every 6 months for the patients receiving amiodarone. Patients were provided with electrocardiographic monitors capable of transmitting data over the telephone and were instructed to transmit an electrocardiogram if cardiac symptoms occurred.
The primary end point was the length of time to a first electrocardiographically confirmed recurrence of atrial fibrillation. Only episodes lasting longer than 10 minutes (as indicated by the history) were considered to be clinically significant. For the purpose of the primary end point, day 21 after randomization was considered to be the beginning of follow-up (day 0). Patients in whom sinus rhythm was not achieved within 21 days after randomization were classified as having had a recurrence on day 1. Secondary end points were adverse effects related to the study medication, thromboembolic events, and death. The system of Hinkle and Thaler was used to classify deaths.32 All primary outcome events and major clinical events were reviewed by a committee whose members had no other affiliation with the study and were unaware of the treatment assignments.
Statistical Analysis
Summary data are expressed as means ±SD or numbers and percentages of patients. Analyses were performed according to the intention-to-treat principle. Data were censored if the patient died, reached the end of the follow-up period (February 1999), or was lost to follow-up without an occurrence of the primary end point. The cumulative risk of recurrence of atrial fibrillation was estimated by the product-limit method of Kaplan and Meier, and the difference between treatment groups was assessed with the log-rank test.33 The Cox proportional-hazards model was used to calculate relative risk and to investigate potential differences in the effects of the study drugs among subgroups.34 We estimated that the enrollment of 400 patients with symptomatic atrial fibrillation would be necessary in order for the study to achieve a power of more than 0.80 to detect a reduction of 30 percentage points in the rate of recurrence of atrial fibrillation in the amiodarone group with a two-sided alpha level of 0.05, assuming a recurrence rate of 50 percent at one year in the group assigned to sotalol or propafenone and a 15 percent loss to follow-up.
Results
A total of 403 patients were enrolled: 201 in the group assigned to amiodarone and 202 in the group assigned to sotalol or propafenone (with 101 assigned to each drug). Ten patients (2.5 percent) were lost to follow-up. Thirteen patients who were first randomly assigned to propafenone and 11 patients who were first randomly assigned to sotalol received the other drug during the 21-day period after randomization. Forty-four patients assigned to treatment with amiodarone underwent a total of 48 electrical cardioversions during the 21-day period after randomization, as compared with 63 patients assigned to treatment with sotalol or propafenone, who underwent a total of 84 cardioversions. Among the patients in whom electrical cardioversion was attempted, the procedure was ultimately successful in 77 percent of those assigned to amiodarone and 81 percent of those assigned to sotalol or propafenone.
Base-Line Characteristics
The clinical, electrocardiographic, and echocardiographic characteristics of the patients at the time of enrollment are shown in Table 1Table 1
Base-Line Clinical, Electrocardiographic, and Echocardiographic Characteristics of the Patients.. With the exception of the percentage of patients with left ventricular hypertrophy, there were no significant differences in base-line characteristics between the treatment groups.Therapy
Table 2Table 2
Mean Daily Doses of Study Drugs. lists the mean daily doses of the study drugs the patients received. Table 3Table 3
Patients Receiving Concomitant Medication. lists the percentages of patients taking various concomitant medications at base line and during follow-up.Recurrence of Atrial Fibrillation
Over the course of a mean follow-up period of 468±150 days, 71 patients assigned to amiodarone (35 percent) had first recurrences of atrial fibrillation, as did 127 of the patients assigned to sotalol or propafenone (63 percent, P<0.001). The median length of time to a recurrence was 98 days for the patients assigned to sotalol or propafenone. No median time could be calculated for the amiodarone group, because more than 50 percent of the patients in this group remained in sinus rhythm without recurrence of atrial fibrillation at the end of follow-up (therefore the median time was more than 468 days).
Figure 1AFigure 1
Kaplan–Meier Estimates of the Percentage of Patients Remaining Free of Recurrence of Atrial Fibrillation. shows the actuarial probability of remaining in sinus rhythm without a recurrence of atrial fibrillation for both treatment groups. Ninety-three percent of the patients assigned to amiodarone and 81 percent of the patients assigned to sotalol or propafenone were in sinus rhythm at the beginning of follow-up, 21 days after randomization. The probability of remaining in sinus rhythm for one year without a recurrence of atrial fibrillation was higher among the patients assigned to amiodarone (69 percent) than among those assigned to sotalol or propafenone (39 percent, P<0.001). For the patients in the amiodarone group, the hazard ratio for a recurrence was 0.43, reflecting a 57 percent reduction in the risk of recurrence of atrial fibrillation. Similarly, when the analysis included only the 350 patients who were in sinus rhythm 21 days after randomization, the actuarial probability of remaining free of a recurrence of atrial fibrillation was significantly higher among the patients assigned to amiodarone than among those assigned to sotalol or propafenone (Figure 1B). As Figure 1C shows, the rate of recurrence of atrial fibrillation was virtually the same for the patients assigned to sotalol and those assigned to propafenone.Subgroups
Figure 2Figure 2
Hazard Ratios and 95 Percent Confidence Intervals for the Recurrence of Atrial Fibrillation in the Amiodarone Group as Compared with the Group Assigned to Sotalol or Propafenone. shows the hazard ratios for the recurrence of atrial fibrillation according to a variety of dichotomous base-line, clinical, and echocardiographic characteristics. The hazard ratios did not differ significantly according to any of these variables; moreover, all 95 percent confidence intervals included the overall hazard ratio and did not include 1.0.Major Clinical Events
During the course of the study, nine patients assigned to amiodarone died, as compared with eight assigned to sotalol or propafenone. Four deaths were presumed to be due to arrhythmia; three of these four occurred in patients assigned to amiodarone (two of these had discontinued the drug for more than one year before death). One patient in each group died of acute myocardial infarction. One patient assigned to sotalol or propafenone died of congestive heart failure. Death was due to a vascular cause in one patient assigned to amiodarone (mesenteric infarction) and in one assigned to sotalol or propafenone (stroke). The cause of death was noncardiovascular for four patients in each group (five died of cancer, and three of other causes).
Thirty-six patients assigned to amiodarone (18 percent) were treated for a total of 45 nonfatal major clinical events, and 35 patients assigned to sotalol or propafenone (17 percent) were treated for 42 such events. Among these events, not all of which are described here, one patient receiving propafenone was resuscitated from cardiac arrest due to torsade de pointes. Congestive heart failure requiring intravenous therapy occurred in 11 patients assigned to amiodarone and 9 assigned to sotalol or propafenone. Strokes and intracranial hemorrhages were less common among the patients assigned to amiodarone than among those assigned to sotalol or propafenone (one patient vs. nine patients, P=0.01). Eight of these patients (one patient assigned to amiodarone and seven assigned to sotalol or propafenone) were receiving warfarin at the time of the event. Two patients in each group had a major hemorrhage in a location other than the nervous system. There were 7 cancers (3 among patients assigned to amiodarone and 4 among patients assigned to sotalol or propafenone) and 13 other nonfatal events (8 and 5, respectively).
Discontinuation of Study Drug
Overall, 68 of the patients assigned to amiodarone (34 percent) and 93 of those assigned to sotalol or propafenone (46 percent) stopped taking the study medication (P=0.01). Seventeen patients assigned to amiodarone (8 percent) discontinued taking the study drug because of a lack of efficacy (defined as frequent recurrences of atrial fibrillation or the need for repeated cardioversion), as compared with 56 assigned to sotalol or propafenone (28 percent, P<0.001). Fifteen patients assigned to amiodarone (7 percent) and 14 assigned to sotalol or propafenone (7 percent) were noncompliant with the study protocol or discontinued taking the medication for other reasons. Thirty-six patients assigned to amiodarone (18 percent) discontinued taking the study drug because of adverse events, as compared with 23 assigned to sotalol or propafenone (11 percent, P=0.06).
The incidence of cardiac events requiring permanent discontinuation of the study medication was similar in the two groups: ventricular tachycardia, none in the amiodarone group and one in the group assigned to sotalol or propafenone; prolongation of the QT interval, one and none, respectively; heart failure, two and three; and serious bradyarrhythmias, six and seven. The most common noncardiac adverse events responsible for discontinuation of the study medication were gastrointestinal events (eight patients in the amiodarone group and three in the group assigned to sotalol or propafenone), central nervous system events (two and one, respectively), insomnia or fatigue (six and four), and visual or dermatologic events (two and one).
Treatment with amiodarone was discontinued in four patients (2 percent) because of pulmonary abnormalities. Although amiodarone-induced pulmonary toxicity is difficult to prove, the diagnosis was felt to be definite in one patient and possible in three. Pulmonary toxicity was suspected in one other patient in whom pulmonary abnormalities developed two months after the discontinuation of amiodarone due to a lack of efficacy. No patient died as a result of pulmonary toxicity. Treatment with amiodarone was discontinued in two patients because of hypothyroidism and in one because of hyperthyroidism. Five patients (two assigned to amiodarone and three assigned to sotalol or propafenone) discontinued treatment because of other reasons.
Discussion
The results of this large, randomized trial show that amiodarone is more effective than sotalol or propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation.
The difference in efficacy we observed is striking; amiodarone was about twice as effective as two commonly used antiarrhythmic agents in preventing recurrences of atrial fibrillation. Our findings indicate that amiodarone warrants consideration as first- or second-line therapy in patients in whom maintenance of sinus rhythm is desired. No difference was found in the occurrence of atrial fibrillation between the patients who received sotalol and those who received propafenone, a finding that is compatible with previous observations.18 Furthermore, the rates of recurrence in the patients treated with these agents in our study were very similar to those reported for patients treated with other class I drugs, such as quinidine and flecainide.14,21,22
Amiodarone was generally well tolerated, and serious adverse events were uncommon. No proarrhythmic effect was observed among the patients assigned to amiodarone, and clinically relevant thyroid and pulmonary abnormalities occurred in a small proportion of patients. The proportion of patients in our study who discontinued taking amiodarone because of adverse events (18 percent) was lower than that previously reported in other large trials.35,36 At one year, more patients in the amiodarone group were still receiving the drug to which they had been assigned (72 percent) than was the case in the group receiving sotalol or propafenone (58 percent). The adverse effects associated with amiodarone have usually been related to the dose and duration of therapy, and much of the concern about its use has arisen from experience with high daily doses in patients treated for ventricular tachyarrhythmias.35,37-39 This trial provides additional information regarding the safety of low doses of amiodarone (200 mg per day or less) for the treatment of atrial fibrillation.
Whether maintaining sinus rhythm in patients with atrial fibrillation will translate into improved survival or a reduction in the risk of thromboembolic events will require further study. Mortality was not the primary outcome measured in this trial, for several reasons. First, the absolute mortality among patients with atrial fibrillation is relatively low, and death is due primarily to associated cardiovascular diseases, making the sample needed for a study of mortality extremely large. Second, the ongoing Atrial Fibrillation Follow-up Investigation of Rhythm Management of the National Heart, Lung, and Blood Institute is comparing the mortality associated with various approaches to treating atrial fibrillation in older patients who have one or more risk factors for stroke. Finally, our study was designed to identify the most effective agent for maintaining sinus rhythm in a heterogeneous group of patients for whom the clinical decision to try to suppress atrial fibrillation had already been made. This information may help in designing subsequent trials with mortality as an end point.
Since this was a relatively short study, it did not address the potential for serious long-term adverse effects associated with low-dose amiodarone. Since the goal of this trial was to compare the relative efficacy of two treatments in patients believed by their physicians to require drug therapy for the maintenance of sinus rhythm, the use of a placebo group was deemed inappropriate. An open-label design was selected, because it would have been technically difficult to maintain blinding in a two-treatment study in which three drugs with different pharmacokinetics, pharmacodynamics, dosing regimens, and safety profiles were used. To minimize the potential effects of bias, the primary end point (recurrence of atrial fibrillation) had to be objectively confirmed by electrocardiography. In addition, all primary end points and fatal and nonfatal major events were reviewed by an independent committee, the members of which were unaware of the treatment assignments.
Overall, we found that amiodarone was more effective in preventing recurrences of atrial fibrillation than two widely used antiarrhythmic drugs. Even recognizing the limitations of the study, we believe that our results challenge the notion that amiodarone should be used only in patients whose conditions are resistant to other drugs. Since other antiarrhythmic agents are less effective and are associated with higher risks,11,22,40 and the safety of amiodarone with regard to cardiovascular complications is well recognized,36 amiodarone should be a drug of choice for patients with recurrent atrial fibrillation and structural heart disease, particularly those with left ventricular dysfunction. Amiodarone should also be considered for patients with refractory conditions who do not have heart disease, before therapies with irreversible effects, such as atrioventricular-nodal ablation, are attempted. Finally, new class III antiarrhythmic agents are currently being evaluated as treatments for atrial fibrillation in placebo-controlled trials. Comparative safety and efficacy data from well-controlled studies of other accepted therapies should complement the findings of these trials. Amiodarone seems an obvious choice for such comparisons.
Supported by an operating grant from the Medical Research Council of Canada.
We are indebted to the study patients for their cooperation and to the study personnel for their assistance; to Luce Bégin for preparing the manuscript; to Dr. Jean L. Rouleau for his encouragement during the study; and to Dr. Martial G. Bourassa for his encouragement and editorial assistance.
Source Information
From the Montreal Heart Institute, Montreal (D.R., M.T., M.J.E., J.L., M.D., P.G., S.N., B.T.); St. Michael's Hospital, Toronto (P.D.); Hamilton General Hospital and McMaster University, Hamilton, Ont. (S.C.); the University of Ottawa Heart Institute, Ottawa, Ont. (M.G.); and Hôpital du Sacré-Cœur de Montréal, Montreal (T.K.) — all in Canada.
Address reprint requests to Dr. Roy at the Montreal Heart Institute, 5000 Belanger St. E., Montreal, QC H1T 1C8, Canada, or at roy@icm.umontreal.ca.
The institutions and investigators participating in the trial are listed in the Appendix.
Appendix
The study sites and investigators of the Canadian Trial of Atrial Fibrillation are listed below in descending order according to the number of patients randomized. For each site, the first person listed was the principal investigator: St. Michael's Hospital and Satellite Centers (Northwestern General Hospital, Scarborough General Hospital, Scarborough Centenary Hospital, Peel Memorial Hospital, York Finch Hospital, Scarborough Grace Hospital, Etobicoke General Hospital, Humber Memorial Hospital, North York General Hospital, Toronto East General Hospital, Oshawa General Hospital, York County Hospital), Toronto: P. Dorian, D. Newman, and J. Mitchell; Institut de Cardiologie de Montréal, Montreal: D. Roy, M. Talajic, M. Dubuc, B. Thibault, P. Gagné, and D. Beaudoin; Centre Hospitalier Régional de Lanaudière, Joliette, Que.: S. Kouz, G.S. Kiwan, J.-P. Deschamps, H. Ouimet, M. Laforest, M. Roy, and C. Rémillard; Hôpital Santa Cabrini, Montreal: O. Ruscito and S. Vinci; Centre Hospitalier Le Gardeur, Repentigny, Que.: G. Gosselin, M. David, and C. Côté; University of Alberta Hospital, Edmonton, Alta.: K. Kavanagh and R. Tabler; Réseau Santé Richelieu-Yamaska, Saint-Hyacinthe, Que.: D. Grandmont, C. Van Kieu, and B. Lecours; Sunnybrook Health Sciences Center, North York, Ont.: Z. Wulffhart, C. Joyner, and M. Aprile; Hôpital Notre-Dame, Montreal: B. Coutu, C. Guimond, and J. Frenette; Centre Hospitalier Pierre-Boucher, Longueuil, Que.: A. Ouellet and L. Leroux; Hôpital Jean-Talon, Montreal: R. Castan, B. Descoings, and A. Beaudoin; Institut de Cardiologie de Québec, Sainte-Foy, Que.: G. O'Hara and L. Charbonneau; Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.: R. Harvey and A. Maltais; Hôpital du Sacré-Cœur de Montréal, Montreal: T. Kus, F. Molin, and G. Gaudette; Toronto General Hospital, Toronto: E. Downar and C. Hale; Hamilton General Hospital, McMaster University, Hamilton, Ont.: S. Connolly, C. Le Feuvre, S. Kahn, and S. Morgan; Cité de la Santé de Laval, Laval, Que.: R. Gendreau and R. Couturier; Hôpital Maisonneuve-Rosemont, Montreal: D. Gossard and C. Roy; University of Ottawa Heart Institute, Ottawa, Ont.: M. Green, A. Tang, and M. Luce. Steering Committee: D. Roy (chair), M. Talajic (co-chair), P. Dorian, S. Connolly, M. Green, T. Kus, M.J. Eisenberg, A. Ciampi, and M. Morello; External Safety and Efficacy Monitoring Committee: G. Dagenais (chair), R. Nadeau, R. Roberts, and M. Tech; Validation and Events Committee: I. Dyrda (chair), J. Diodati, J. Nasmith, and N. Racine; Coordinating and Methods Center: Montreal Heart Institute, Faculty of Medicine, University of Montreal, Montreal — D. Roy and M. Talajic (principal investigators); B. Thibault, M. Dubuc, M. Morello, C. Dupont, A. Couturier, J. Lambert, M.J. Eisenberg, and S. Nattel.
- References
References
1
Kannel WB ,Abbott RD ,Savage DD ,McNamara PM . Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018-1022
Full Text | Web of Science | Medline2
Feinberg WM ,Blackshear JL ,Laupacis A ,Kronmal R ,Hart RG . Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-473
CrossRef | Web of Science | Medline3
Braunwald E . Shattuck Lecture -- cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-1369
Full Text | Web of Science | Medline4
Morris JJ Jr ,Entman M ,North WC ,Kong Y ,McIntosh H . The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. Circulation 1965;31:670-678
Web of Science | Medline5
Shapiro W ,Klein G . Alterations in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm. Circulation 1968;38:1074-1084
Web of Science | Medline6
Lewis RV ,Irvine N ,McDevitt DG . Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9:777-781
Web of Science | Medline7
Gosselink ATM ,Crijns HJGM ,van den Berg MP . Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994;72:161-166
CrossRef | Web of Science | Medline8
Pritchett ELC . Management of atrial fibrillation. N Engl J Med 1992;326:1264-1271
Full Text | Web of Science | Medline9
Wolf PA ,Abbott RD ,Kannel WB . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988
CrossRef | Web of Science | Medline10
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457[Erratum, Arch Intern Med 1994;154:2254.]
CrossRef | Web of Science | Medline11
Coplen SE ,Antman EM ,Berlin JA ,Hewitt P ,Chalmers TC . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990;82:1106-1116[Erratum, Circulation 1991;83:714.]
CrossRef | Web of Science | Medline12
Dethy M ,Chassat C ,Roy D ,Mercier L-A . Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol 1988;62:723-726
CrossRef | Web of Science | Medline13
Van Gelder IC ,Crijns HJ ,Van Gilst WH ,Verwer R ,Lie KI . Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41-46
CrossRef | Web of Science | Medline14
Juul-Moller S ,Edvardsson N ,Rehnqvist-Ahlberg N . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939
CrossRef | Web of Science | Medline15
Connolly SJ ,Hoffert DL . Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-819
CrossRef | Web of Science | Medline16
Pritchett ELC ,McCarthy EA ,Wilkinson WE . Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-544
Web of Science | Medline17
Antman EM ,Beamer AD ,Cantillon C ,McGowan N ,Goldman L ,Friedman PL . Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12:1005-1011[Erratum, J Am Coll Cardiol 1989;13:264.]
CrossRef | Web of Science | Medline18
Reimold SC ,Cantillon CO ,Friedman PL ,Antman EM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563
CrossRef | Web of Science | Medline19
Van Gelder IC ,Crijns HJGM ,Van Gilst WH ,Van Wijk LM ,Hamer HPM ,Lie KI . Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321
CrossRef | Web of Science | Medline20
Anderson JL ,Gilbert EM ,Alpert BL , et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-1570
CrossRef | Web of Science | Medline21
Naccarelli GV ,Dorian P ,Hohnloser SH ,Coumel P . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:A53-A59
CrossRef | Web of Science | Medline22
Nattel S ,Hadjis T ,Talajic M . The treatment of atrial fibrillation: an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-371
CrossRef | Web of Science | Medline23
Flaker GC ,Blackshear JL ,McBride R ,Kronmal RA ,Halperin JL ,Hart RG . Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532
CrossRef | Web of Science | Medline24
Middlekauff HR ,Wiener I ,Stevenson WG . Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993;72:75F-81F
CrossRef | Web of Science | Medline25
Vitolo E ,Tronci M ,Larovere MT ,Rumolo R ,Morabito A . Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;36:431-444
Web of Science | Medline26
Gosselink AT ,Crijns HJ ,Van Gelder IC ,Hillige H ,Wiesfeld ACP ,Lie KI . Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-3293
CrossRef | Web of Science | Medline27
Chun SH ,Sager PT ,Stevenson WG ,Nademanee K ,Middlekauff HR ,Singh BN . Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50
CrossRef | Web of Science | Medline28
Zarembski DG ,Nolan PE Jr ,Slack MK ,Caruso AC . Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995;155:1885-1891
CrossRef | Web of Science | Medline29
Kochiadakis GE ,Igoumenidis NE ,Marketou ME ,Solomou MC ,Kanoupakis EM ,Vardas PE . Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995-998
CrossRef | Web of Science | Medline30
Roy D ,Talajic M ,Thibault B , et al. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Am J Cardiol 1997;80:464-468
CrossRef | Web of Science | Medline31
Talajic M ,MacDonald RG ,Nattel S . Restoration of sinus rhythm in patients with atrial fibrillation. Can J Cardiol 1996;12:Suppl A:29A-35A
Medline32
Hinkle LE Jr ,Thaler HT . Clinical classification of cardiac deaths. Circulation 1982;65:457-464
CrossRef | Web of Science | Medline33
Mantel M . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline34
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22035
Vorperian VR ,Havighurst TC ,Miller S ,January CT . Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791-798
CrossRef | Web of Science | Medline36
Amiodarone Trials Meta-Analysis Investigators
CrossRef | Web of Science | Medline37
Mason JW . Amiodarone. N Engl J Med 1987;316:455-466
Full Text | Web of Science | Medline38
Collaborative Group for Amiodarone Evaluation
CrossRef | Web of Science | Medline39
Raeder EA ,Podrid PJ ,Lown B . Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975-983
CrossRef | Web of Science | Medline40
Teo KK ,Yusuf S ,Furberg CD . Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993;270:1589-1595
CrossRef | Web of Science | Medline
- Citing Articles (275)
Citing Articles
1
M. D. Smit, A. H. Maass, A. M. De Jong, A. C. Muller Kobold, D. J. Van Veldhuisen, I. C. Van Gelder. (2012) Role of inflammation in early atrial fibrillation recurrence. Europace
CrossRef2
Chern-En Chiang, Shu Zhang, Hung Fat Tse, Wee Siong Teo, Razali Omar, Charn Sriratanasathavorn. (2012) Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation. International Journal of Cardiology
CrossRef3
Christian Jons, Poul Erik Bloch Thomsen. (2011) Treating Cardiac Arrhythmias Detected With an Implantable Cardiac Monitor in Patients After an Acute Myocardial Infarction. Current Treatment Options in Cardiovascular Medicine
CrossRef4
Marc Cohen, Catalin Boiangiu. (2011) The Management of Patients with Atrial Fibrillation and Dronedarone’s Place in Therapy. Advances in Therapy
CrossRef5
Alexander Burashnikov, Charles Antzelevitch. (2011) Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacology & Therapeutics 132:3, 300-313
CrossRef6
AVINASH R. KHITRI, ETIENNE M. ALIOT, ALESSANDRO CAPUCCI, STUART J. CONNOLLY, HARRY CRIJNS, STEFAN H. HOHNLOSER, PIOTR KULAKOWSKI, DENIS ROY, DAVID RADZIK, PETER R. KOWEY. (2011) Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. Journal of Cardiovascular Electrophysiologyno-no
CrossRef7
Pedram Kazemian, Gavin Oudit, Bodh I. Jugdutt. (2011) Atrial fibrillation and heart failure in the elderly. Heart Failure Reviews
CrossRef8
Ihor Gussak, Dejan Vukajlovic, Vladan Vukcevic, Samuel George, Bosko Bojovic, Ljupco Hadzievski, Goran Simic, Bojan Stojanovic, Lazar Angelkov, Dorin Panescu. (2011) Wireless remote monitoring of reconstructed 12-lead ECGs after ablation for atrial fibrillation using a hand-held device. Journal of Electrocardiology
CrossRef9
IVAN CAKULEV, ANTONIO E. LACERDA, CELEEN M. KHRESTIAN, KYUNGMOO RYU, ARTHUR M. BROWN, ALBERT L. WALDO. (2011) Oral Vanoxerine Prevents Reinduction of Atrial Tachyarrhythmias: Preliminary Results. Journal of Cardiovascular Electrophysiology 22:11, 1266-1273
CrossRef10
Michael H. Kim, Paula J. Smith, Mehul Jhaveri, Jay Lin, David Klingman. (2011) One-Year Treatment Persistence and Potential Adverse Events Among Patients With Atrial Fibrillation Treated With Amiodarone or Sotalol: A Retrospective Claims Database Analysis. Clinical Therapeutics 33:11, 1668-1681.e1
CrossRef11
I. C. Van Gelder, L. M. Haegeli, A. Brandes, H. Heidbuchel, E. Aliot, J. Kautzner, L. Szumowski, L. Mont, J. Morgan, S. Willems, S. Themistoclakis, M. Gulizia, A. Elvan, M. D. Smit, P. Kirchhof. (2011) Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 13:11, 1517-1525
CrossRef12
RAÚL ALCARAZ, FERNANDO HORNERO, JOSÉ J. RIETA. (2011) Noninvasive Time and Frequency Predictors of Long-Standing Atrial Fibrillation Early Recurrence after Electrical Cardioversion. Pacing and Clinical Electrophysiology 34:10, 1241-1250
CrossRef13
Eiichi Watanabe, Yoshihiro Sobue, Kan Sano, Kentarou Okuda, Mayumi Yamamoto, Yukio Ozaki. (2011) Eicosapentaenoic Acid for the Prevention of Recurrent Atrial Fibrillation. Annals of Noninvasive Electrocardiology 16:4, 373-378
CrossRef14
L. R. C. Dekker. (2011) Treatment of atrial fibrillation in the elderly: time for a change?. Netherlands Heart Journal 19:10, 403-404
CrossRef15
Sheba Ahmed, Isabelle C. Van Gelder, Ans C. P. Wiesfeld, Dirk J. Van Veldhuisen, Thera P. Links. (2011) Determinants and outcome of amiodarone-associated thyroid dysfunction. Clinical Endocrinology 75:3, 388-394
CrossRef16
Shinsuke Miyazaki, Ashok J. Shah, Daniel Scherr, Michel Haïssaguerre. (2011) Atrial fibrillation: Pathophysiology and current therapy. Annals of Medicine 43:6, 425-436
CrossRef17
Carlos de Diego Rus, Jesús Almendral Garrote. (2011) El tratamiento de la fibrilación auricular: ¿una cuestión de perspectiva?. Medicina Clínica 137:6, 257-258
CrossRef18
Marcello Disertori, Federico Lombardi, Simona Barlera, Aldo Pietro Maggioni, Chiara Favero, Maria Grazia Franzosi, Donata Lucci, Lidia Staszewsky, Gianna Fabbri, Silvia Quintarelli, Leopoldo Bianconi, Roberto Latini. (2011) Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial. American Heart Journal 162:2, 382-389
CrossRef19
Alexandra Perez, Daniel R Touchette, Robert J DiDomenico, Thomas D Stamos, Surrey M Walton. (2011) Comparison of Rate Control versus Rhythm Control for Management of Atrial Fibrillation in Patients with Coexisting Heart Failure: A Cost-Effectiveness Analysis. Pharmacotherapy 31:6, 552-565
CrossRef20
John Camm. (2011) Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits. International Journal of Cardiology
CrossRef21
Michele Marzocchi, Federico Lombardi. (2011) Dronedarone for atrial fibrillation therapy. Expert Review of Cardiovascular Therapy 9:6, 675-683
CrossRef22
Sony Jacob, Omaima A Ali, Victoria Pidlaoan, Apurva O Badheka, Nicholas Z Kerin. (2011) Pharmacotherapy of Atrial Fibrillation: A Pathophysiological Perspective and Review. American Journal of Therapeutics 18:3, 241-260
CrossRef23
ALBERTO LOMUSCIO, SEBASTIANO BELLETTI, PIER MARIA BATTEZZATI, FEDERICO LOMBARDI. (2011) Efficacy of Acupuncture in Preventing Atrial Fibrillation Recurrences After Electrical Cardioversion. Journal of Cardiovascular Electrophysiology 22:3, 241-247
CrossRef24
N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, M. Reynolds. (2011) Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13:3, 329-345
CrossRef25
JAMES A. REIFFEL. (2011) Atrial Fibrillation: What Have Recent Trials Taught Us Regarding Pharmacologic Management of Rate and Rhythm Control?. Pacing and Clinical Electrophysiology 34:2, 247-259
CrossRef26
Stephan Geidel, Korff Krause, Sigrid Boczor, Karl-Heinz Kuck, Michael Lass, Jörg Ostermeyer, Michael Schmoeckel. (2011) Ablation surgery in patients with persistent atrial fibrillation: An 8-year clinical experience. The Journal of Thoracic and Cardiovascular Surgery 141:2, 377-382
CrossRef27
Yasuyuki Egami, Masami Nishino, Masayuki Taniike, Nobuhiko Makino, Hiroyasu Kato, Ryu Shutta, Jun Tanouchi, Yoshio Yamada. (2011) Efficacy and Safety of Bepridil for Patients with Persistent Atrial Fibrillation after Failed Electrical Cardioversion. Journal of Arrhythmia 27:2, 131-136
CrossRef28
Kenan Demir, Ilknur Can, Fatih Koc, Mehmet Akif Vatankulu, Selim Ayhan, Hakan Akilli, Alpay Aribas, Yusuf Alihanoglu, Bulent Behlul Altunkeser. (2011) Atorvastatin Given prior to Electrical Cardioversion Does Not Affect the Recurrence of Atrial Fibrillation in Patients with Persistent Atrial Fibrillation Who Are on Antiarrhythmic Therapy. Medical Principles and Practice 20:5, 464-469
CrossRef29
Juan F. Viles-Gonzalez, Valentin Fuster, Jonathan Halperin, Hugh Calkins, Vivek Y. Reddy. (2011) Rhythm Control for Management of Patients With Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation. Clinical Cardiology 34:1, 23-29
CrossRef30
Razali Omar, Wee Siong Teo, David Foo, Chee Kok Han, Ahmad Nizar Jamaluddin, Lip Ping Low, Tiong Kiam Ong. (2011) Atrial Fibrillation in Singapore and Malaysia: Current Trends and Future Prospects. Journal of Arrhythmia 27:3, 171-185
CrossRef31
J.-Y. Le Heuzey. (2010) Prise en charge de la fibrillation atriale, ce qu’il faut savoir sur les anciens et les nouveaux anti-arythmiques. Annales de Cardiologie et d'Angéiologie 59, S24-S27
CrossRef32
A. Leenhardt, G. Moubarak, A. Messali, F. Extramiana. (2010) La fibrillation atriale est-elle un marqueur indépendant de risque cardio-vasculaire ?. Annales de Cardiologie et d'Angéiologie 59, S14-S18
CrossRef33
C. Sohns, M. Zabel. (2010) Aktueller Stellenwert von Amiodaron in der antiarrhythmischen Therapie. Herzschrittmachertherapie + Elektrophysiologie 21:4, 239-243
CrossRef34
Saumy Sharma, Trieu Ho, Bharat Kantharia. 2010. Cardiac Antiarrhythmic Agents. .
CrossRef35
Mark Alber Meshil, Deepak Bhakta. (2010) REVIEW: Nonpharmacological Therapies for Atrial Fibrillation. Cardiovascular Therapeutics 28:5, 264-277
CrossRef36
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 31:19, 2369-2429
CrossRef37
Stavros Mountantonakis, Rajat Deo. (2010) Biomarkers in Atrial Fibrillation, Ventricular Arrhythmias, and Sudden Cardiac Death. Cardiovascular Therapeuticsno-no
CrossRef38
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:10, 1360-1420
CrossRef39
Jason G. Andrade, Stuart J. Connolly, Paul Dorian, Martin Green, Karin H. Humphries, George J. Klein, Robert Sheldon, Mario Talajic, Charles R. Kerr. (2010) Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Heart Rhythm 7:9, 1171-1177
CrossRef40
A. Arya, J. S. Silberbauer, J. Vrahimides, E. Cheek, A. Mitchell, L. Boodhoo, P. Pugh, J. Large, G. Bordoli, W. Taggu, G. W. Lloyd, N. R. Patel, A. N. Sulke. (2010) First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes. International Journal of Clinical Practice 64:8, 1062-1068
CrossRef41
Alessandro Marinelli, Alessandro Rosi, Alessandro Capucci. (2010) Role of sotalol in rhythm control of atrial fibrillation. Therapy 7:4, 391-407
CrossRef42
S. Ahmed, A. V. Ranchor, H. J. G. M. Crijns, D. J. Van Veldhuisen, I. C. Van Gelder, . (2010) Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. Europace 12:6, 785-791
CrossRef43
Steven Baroletti, Jennifer Catella, Michael Ehle, Judy W. M. Cheng. (2010) Dronedarone. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:2, 94-101
CrossRef44
JEAN-YVES LE HEUZEY, GAETANO M. DE FERRARI, DAVID RADZIK, MASSIMO SANTINI, JUNREN ZHU, JEAN-MARC DAVY. (2010) A Short-Term, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study. Journal of Cardiovascular Electrophysiology 21:6, 597-605
CrossRef45
Marcello Disertori, Federico Lombardi, Simona Barlera, Roberto Latini, Aldo P. Maggioni, Prisca Zeni, Giuseppe Di Pasquale, Franco Cosmi, Maria Grazia Franzosi. (2010) Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial. American Heart Journal 159:5, 857-863
CrossRef46
I. Nault, S. Miyazaki, A. Forclaz, M. Wright, A. Jadidi, P. Jais, M. Hocini, M. Haissaguerre. (2010) Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. European Heart Journal 31:9, 1046-1054
CrossRef47
Dobromir Dobrev, Stanley Nattel. (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. The Lancet 375:9721, 1212-1223
CrossRef48
Christian Torp-Pedersen, Ole Dyg Pedersen, Lars Køber. (2010) Antiarrhythmic Drugs. Journal of the American College of Cardiology 55:15, 1577-1579
CrossRef49
David Singh, Eugenio Cingolani, George A. Diamond, Sanjay Kaul. (2010) Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology 55:15, 1569-1576
CrossRef50
Alexander Burashnikov, Charles Antzelevitch. (2010) New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology 7:3, 139-148
CrossRef51
Dobromir Dobrev. (2010) Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn-Schmiedeberg's Archives of Pharmacology 381:3, 195-206
CrossRef52
Clemens Steinwender, Simon Hönig, Franz Leisch, Robert Hofmann. (2010) Clinical experience with routine use of a single combined mapping and ablation catheter for isolation of pulmonary veins in patients with paroxysmal atrial fibrillation. Wiener klinische Wochenschrift 122:5-6, 146-151
CrossRef53
Thorsten Lewalter. (2010) Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 55:10, 1051-1052
CrossRef54
Jean-Benoît le Polain de Waroux, Mario Talajic, Paul Khairy, Peter G Guerra, Denis Roy, Bernard Thibault, Marc Dubuc, Laurent Macle. (2010) Pulmonary vein isolation for the treatment of atrial fibrillation: past, present and future. Future Cardiology 6:1, 51-66
CrossRef55
Thomas H. Hauser, Dana C. Peters. 2010. Pulmonary Vein Imaging. , 441-449.
CrossRef56
Saumy Sharma, Trieu Ho, Bharat Kantharia. 2010. .
CrossRef57
Sook Kyoung Kim, Hui-Nam Pak, Jae Hyung Park, Kyoung Jeong Ko, Jihei Sara Lee, Jin Wi, Jong Il Choi, Young-Hoon Kim. (2010) Serological Predictors for the Recurrence of Atrial Fibrillation After Electrical Cardioversion. Korean Circulation Journal 40:4, 185
CrossRef58
Jens Seiler, William G. Stevenson. (2010) Atrial Fibrillation in Congestive Heart Failure. Cardiology in Review 18:1, 38-50
CrossRef59
Marcus L. Koller, Burghard Schumacher. (2010) Medikamentöse Therapie von Herzrhythmusstörungen. Medizinische Klinik 105:1, 26-40
CrossRef60
Michael H Kim, David Klingman, Jay Lin, David S Battleman. (2009) Patterns and Predictors of Discontinuation of Rhythm-Control Drug Therapy in Patients with Newly Diagnosed Atrial Fibrillation. Pharmacotherapy 29:12, 1417-1426
CrossRef61
Ph. Chevalier. (2009) Traitement anti-arythmique de consolidation du rythme sinusal chez les patients avec fibrillation atriale : une stratégie à privilégier. Annales de Cardiologie et d'Angéiologie 58, S42-S46
CrossRef62
Rakesh Gopinathannair, Renee M. Sullivan, Brian Olshansky. (2009) Tachycardia-mediated cardiomyopathy: Recognition and management. Current Heart Failure Reports 6:4, 257-264
CrossRef63
S. K. Kim, H.-N. Pak, J. H. Park, K. J. Ko, J. S. Lee, J. I. Choi, D. H. Choi, Y.-H. Kim. (2009) Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace 11:12, 1632-1638
CrossRef64
M.H. Kim, J. Lin, M. Hussein, D. Battleman. (2009) Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Current Medical Research and Opinion 25:12, 3037-3047
CrossRef65
JAE HYUNG PARK, HUI-NAM PAK, EUN JEOUNG CHOI, JIN KUN JANG, SOOK KYOUNG KIM, DONG HOON CHOI, JONG IL CHOI, CHUN HWANG, YOUNG-HOON KIM. (2009) The Relationship Between Endocardial Voltage and Regional Volume in Electroanatomical Remodeled Left Atria in Patients with Atrial Fibrillation: Comparison of Three-Dimensional Computed Tomographic Images and Voltage Mapping. Journal of Cardiovascular Electrophysiology 20:12, 1349-1356
CrossRef66
H.-J. Trappe. (2009) Antiarrhythmische Therapie mit Amiodaron bei tachykarden Rhythmusstörungen. Intensivmedizin und Notfallmedizin 46:8, 563-572
CrossRef67
A. P. Maggioni, G. Fabbri, D. Lucci, R. Marchioli, M. G. Franzosi, R. Latini, G. L. Nicolosi, M. Porcu, F. Cosmi, S. Stefanelli, G. Tognoni, L. Tavazzi, . (2009) Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. European Heart Journal 30:19, 2327-2336
CrossRef68
Patrick P. Kneeland, Margaret C. Fang. (2009) Trends in catheter ablation for atrial fibrillation in the United States. Journal of Hospital Medicine 4:7, E1-E5
CrossRef69
NASSIR F. MARROUCHE, JOHANNES BRACHMANN, . (2009) Catheter Ablation versus Standard Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE-AF) - Study Design. Pacing and Clinical Electrophysiology 32:8, 987-994
CrossRef70
X. Lan, L. Su, Z. Ling, Z. Liu, J. Wu, X. Yang, B. Zrenner, Y. Yin. (2009) Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation. European Journal of Clinical Investigation 39:8, 657-663
CrossRef71
Rakesh Gopinathannair, Renee M. Sullivan, Brian Olshansky. (2009) Update on medical management of atrial fibrillation in the modern era. Heart Rhythm 6:8, S17-S22
CrossRef72
Richard Lee, Jane Kruse, Patrick M. McCarthy. (2009) Surgery for atrial fibrillation. Nature Reviews Cardiology 6:8, 505-513
CrossRef73
Mohammed Reza Moussavian, Otto Kollmar, Michael Schmidt, Claudia Scheuer, Matthias Wagner, Jan Erik Slotta, Gernot Gronow, Christoph Justinger, Michael Dieter Menger, Martin Karl Schilling. (2009) Amiodarone pretreatment of organ donors exerts anti-oxidative protection but induces excretory dysfunction in liver preservation and reperfusion. Liver Transplantation 15:7, 763-775
CrossRef74
KATHERINE T. MURRAY. (2009) Why Amiodarone is Better: Another Piece of the Puzzle. Journal of Cardiovascular Electrophysiology 20:7, 811-812
CrossRef75
B.-D. Gonska, H.J. Bauerle, T. Japha. (2009) Vorhofflimmerablation: Wer kommt in Frage?. Herzschrittmachertherapie + Elektrophysiologie 20:2, 76-81
CrossRef76
Fred Kusumoto, Karin Prussak, Melissa Wiesinger, Tammy Pullen, Cynthia Lynady. (2009) Radiofrequency catheter ablation of atrial fibrillation in older patients: outcomes and complications. Journal of Interventional Cardiac Electrophysiology 25:1, 31-35
CrossRef77
Joachim R. Ehrlich, Stanley Nattel. (2009) Novel Approaches for Pharmacological Management of Atrial Fibrillation. Drugs 69:7, 757-774
CrossRef78
The GISSI-AF Investigators. (2009) Valsartan for Prevention of Recurrent Atrial Fibrillation. New England Journal of Medicine 360:16, 1606-1617
Full Text79
Erik Beyer, Richard Lee, Buu-Khanh Lam. (2009) Point: Minimally invasive bipolar radiofrequency ablation of lone atrial fibrillation: Early multicenter results. The Journal of Thoracic and Cardiovascular Surgery 137:3, 521-526
CrossRef80
J. F. Doyle, K. M. Ho. (2009) Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clinic Proceedings 84:3, 234-242
CrossRef81
THOMAS J. VAN BRAKEL, JJ ROB HERMANS, RYAN E. ACCORD, ULRICH SCHOTTEN, JOS FM. SMITS, MAURITS A. ALLESSIE, JOS G. MAESSEN. (2009) Effects of Intrapericardial Sotalol and Flecainide on Transmural Atrial Electrophysiology and Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 20:2, 207-215
CrossRef82
Yuji Nakazato. (2009) The Resurfacing of Bepridil Hydrochloride on the World Stage as an Antiarrhythmic Drug for Atrial Fibrillation. Journal of Arrhythmia 25:1, 4-9
CrossRef83
Paul G Novak. (2009) Effectiveness of catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation. Current Opinion in Cardiology 24:1, 9-17
CrossRef84
T. S. Han, G. R. Williams, M. P. J. Vanderpump. (2009) Benzofuran derivatives and the thyroid. Clinical Endocrinology 70:1, 2-13
CrossRef85
A. Arya, J. Silberbauer, S. L. Teichman, P. Milner, N. Sulke, A. J. Camm. (2008) A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 11:4, 458-464
CrossRef86
A. Verma. (2008) Alternatives to amiodarone: search for the Holy Grail. Europace 11:4, 402-404
CrossRef87
P. Peñafiel Verdú, A. García Alberola, M. Valdés Chávarri. (2008) Manejo de la fibrilación/flutter auricular de reciente comienzo. Medicine - Programa de Formación Médica Continuada Acreditado 10:23, 1540-1546
CrossRef88
Jörn Schmitt, Joachim R. Ehrlich, Stefan H. Hohnloser. (2008) New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation. Herz Kardiovaskuläre Erkrankungen 33:8, 562-567
CrossRef89
Josep Maria Alegret, Xavier Viñolas, Ángel Grande, Eduardo Castellanos, Antonio Asso, Luis Tercedor, José Ramón Carmona, Olga Medina, Arcadio García Alberola, M.ª Luisa Fidalgo, Luisa Pérez-Alvarez, Xavier Sabaté. (2008) Utilidad en la práctica clínica del tratamiento antiarrítmico tras cardioversión eléctrica en pacientes sin cardiopatía estructural. Revista Española de Cardiología 61:12, 1274-1279
CrossRef90
T. H. Hauser, D. C. Peters, J. V. Wylie, W. J. Manning. (2008) Evaluating the left atrium by magnetic resonance imaging. Europace 10:Supplement 3, iii22-iii27
CrossRef91
Imke Drewitz, Thomas Rostock, Boris Hoffmann, Daniel Steven, Helge Servatius, Thomas Meinertz, Stephan Willems, . (2008) Aktuelle Therapiestrategien bei Vorhofflimmern. Medizinische Klinik 103:11, 788-800
CrossRef92
DAVID M. LURIA, DAVID O. HODGE, KRISTI H. MONAHAN, JANIS M. HAROLDSON, WIN-KUANG SHEN, SAMUEL J. ASIRVATHAM, STEPHEN C. HAMMILL, THOMAS M. MUNGER, MICHAEL GLIKSON, BERNARD J. GERSH, DOUGLAS L. PACKER, PAUL A. FRIEDMAN. (2008) Effect of Radiofrequency Ablation of Atrial Flutter on the Natural History of Subsequent Atrial Arrhythmias. Journal of Cardiovascular Electrophysiology 19:11, 1145-1150
CrossRef93
Bramah N Singh. (2008) Amiodarone as Paradigm for Developing New Drugs for Atrial Fibrillation. Journal of Cardiovascular Pharmacology 52:4, 300-305
CrossRef94
V. Ghezel-Ahmadi, V.C. Kürschner, A. Fisseler-Eckhoff, J. Schirren, J.E. Schmitz, T. Obenhaus. (2008) Amiodaroninduzierte Pneumonitis. Der Anaesthesist 57:10, 982-987
CrossRef95
A. J. Camm, J. A. Reiffel. (2008) Defining endpoints in clinical trials on atrial fibrillation. European Heart Journal Supplements 10:Suppl H, H55-H78
CrossRef96
Wilbert S. Aronow. (2008) Treatment of Atrial Fibrillation and Atrial Flutter. Cardiology in Review 16:5, 230-239
CrossRef97
Maryse Palardy, Anique Ducharme, Stanley Nattel, Jean-Claude Tardif, Michel White, Normand Racine, Karine Tétreault, Farida Dabouz, Mario Talajic, Denis Roy. (2008) Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF). Canadian Journal of Cardiology 24:9, 709-713
CrossRef98
Enrique Diaz-Guzman, Eduardo Mireles-Cabodevila, Andrea Arrossi, Jeffrey P. Kanne, Marie Budev. (2008) Amiodarone Pulmonary Toxicity After Lung Transplantation. The Journal of Heart and Lung Transplantation 27:9, 1059-1063
CrossRef99
E. Aliot, J. N. Ruskin. (2008) Controversies in ablation of atrial fibrillation. European Heart Journal Supplements 10:Suppl H, H32-H54
CrossRef100
H. Volkmann, L. Richter, C. Bergmann. (2008) Pharmakologische Therapie bei Vorhofflimmern – Was leisten moderne Antiarrhythmika wirklich?. Clinical Research in Cardiology Supplements 3:1, 101-106
CrossRef101
Stanley Nattel. (2008) Evolving Developments in the Therapeutics of Atrial Fibrillation: Addressing an Unmet Need. Journal of Cardiovascular Pharmacology 52:1, 1-3
CrossRef102
Justin M. Bachmann, Maulik Majmudar, Christine Tompkins, Roger S. Blumenthal, Joseph E. Marine. (2008) Lipid-Altering Therapy and Atrial Fibrillation. Cardiology in Review 16:4, 197-204
CrossRef103
Michael J. Mazzini, Kevin M. Monahan. (2008) Pharmacotherapy for atrial arrhythmias: Present and future. Heart Rhythm 5:6, S26-S31
CrossRef104
Yvonne Smyth, Kieran Daly. 2008. Pharmacological Management of Atrial Fibrillation. , 37-47.
CrossRef105
Mustafa Guden, Belhhan Akpynar, Osman Bayndur. 2008. Minimally Invasive Surgical Approach to Treat Atrial Fibrillation. , 191-202.
CrossRef106
Sabine Janko, Uwe Dorwarth, Ellen Hoffmann. (2008) Pharmacotherapy of atrial fibrillation: an old option with new possibilities. Expert Opinion on Pharmacotherapy 9:6, 913-925
CrossRef107
Imad Abi nasr, Nicolas Mansencal, Olivier Dubourg. (2008) Management of atrial fibrillation in heart failure in the elderly. International Journal of Cardiology 125:2, 178-182
CrossRef108
C Michael White. (2008) Is dronedarone effective for the prevention of recurrent atrial fibrillation?. Nature Clinical Practice Cardiovascular Medicine 5:3, 136-137
CrossRef109
Cumhur Kirilmis, Misir Ahmedzade, Süleyman Servi, Murat Koca, Ahmet Kizirgil, Cavit Kazaz. (2008) Synthesis and antimicrobial activity of some novel derivatives of benzofuran: Part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives. European Journal of Medicinal Chemistry 43:2, 300-308
CrossRef110
Joachim R. Ehrlich, Peter Biliczki, Stefan H. Hohnloser, Stanley Nattel. (2008) Atrial-Selective Approaches for the Treatment of Atrial Fibrillation. Journal of the American College of Cardiology 51:8, 787-792
CrossRef111
Wilbert S Aronow, Carmine Sorbera. 2008. Supraventricular Tachyarrhythmias in the Elderly. , 577-604.
CrossRef112
Atul Verma. (2008) Atrial-fibrillation ablation should be considered first-line therapy for some patients. Current Opinion in Cardiology 23:1, 1-8
CrossRef113
Michele Gulizia, Salvatore Mangiameli, Serafino Orazi, Giacomo Chiarandà, Guglielmo Piccione, Nicolò Di Giovanni, Andrea Colletti, Orazio Pensabene, Francesco Lisi, Ludovico Vasquez, Andrea Grammatico, Giuseppe Boriani. (2008) A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. American Heart Journal 155:1, 100.e1-100.e9
CrossRef114
Luca Mainardi, Leif Sörnmo, Sergio Cerutti. (2008) Understanding Atrial Fibrillation: The Signal Processing Contribution, Part I. Synthesis Lectures on Biomedical Engineering 3:1, 1-129
CrossRef115
Tadao Nakazawa, Shin-ichi Murata, Tetsuo Kondo, Nobuki Nakamura, Tetsu Yamane, Satoshi Iwasa, Ryohei Katoh. (2008) Histopathology of the thyroid in amiodarone-induced hypothyroidism. Pathology International 58:1, 55-58
CrossRef116
Yoshihiro Hashimoto. (2008) Research and development strategy of anti-atrial fibrillation agents. Folia Pharmacologica Japonica 131:6, 452-456
CrossRef117
Simone Musco, Emily L. Conway, Peter R. Kowey. (2008) Drug Therapy for Atrial Fibrillation. Medical Clinics of North America 92:1, 121-141
CrossRef118
Benzy J. Padanilam, Eric N. Prystowsky. (2008) Atrial Fibrillation: Goals of Therapy and Management Strategies to Achieve the Goals. Medical Clinics of North America 92:1, 217-235
CrossRef119
DOMINIK K. LINZ, FRENI AFKHAM, GABI ITTER, HARTMUT RÜTTEN, KLAUS J. WIRTH. (2007) Effect of Atrial Electrical Remodeling on the Efficacy of Antiarrhythmic Drugs: Comparison of Amiodarone with I Kr - and I to /IKur-Blockade In Vivo. Journal of Cardiovascular Electrophysiology 18:12, 1313-1320
CrossRef120
Paulus Kirchhof, Andreas Goette, Gerd Hindricks, Stefan Hohnloser, Karl-Heinz Kuck, Thomas Meinertz, Ursula Ravens, Gerhard Steinbeck, Günter Breithardt. (2007) Endpunkte für Studien bei Patienten mit Vorhofflimmern. Herzschrittmachertherapie & Elektrophysiologie 18:4, 259-268
CrossRef121
Y. Blaauw, H. J. G. M. Crijns. (2007) Atrial fibrillation: insights from clinical trials and novel treatment options. Journal of Internal Medicine 262:6, 593-614
CrossRef122
Hikaru Tanaka, Norio Hashimoto. (2007) A Multiple Ion Channel Blocker, NIP-142, for the Treatment of Atrial Fibrillation. Cardiovascular Drug Reviews 25:4, 342-356
CrossRef123
Carmelo Lafuente-Lafuente, Stephane Mouly, Miguel Angel Longas-Tejero, Jean-François Bergmann, Carmelo Lafuente-Lafuente. 2007. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. .
CrossRef124
Thomas C. Crawford, Hakan Oral. (2007) Cardiac Arrhythmias: Management of Atrial Fibrillation in the Critically Ill Patient. Critical Care Clinics 23:4, 855-872
CrossRef125
Singh, Bramah N., Connolly, Stuart J., Crijns, Harry J.G.M., Roy, Denis, Kowey, Peter R., Capucci, Alessandro, Radzik, David, Aliot, Etienne M., Hohnloser, Stefan H., . (2007) Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. New England Journal of Medicine 357:10, 987-999
Full Text126
Ezekowitz, Michael D., . (2007) Maintaining Sinus Rhythm — Making Treatment Better Than the Disease. New England Journal of Medicine 357:10, 1039-1041
Full Text127
Sachin A Shah, Jeffrey Kluger, C. Michael White. (2007) Monotherapy versus Combination Therapy with Class III Antiarrhythmic Agents to Attenuate Transmural Dispersion of Repolarization: A Potential Risk Factor for Torsade de Pointes. Pharmacotherapy 27:9, 1297-1305
CrossRef128
Suveer Bagwe, Marino Leonardi, Joe Bissett. (2007) Novel pharmacological therapies for atrial fibrillation. Current Opinion in Cardiology 22:5, 450-457
CrossRef129
Deepak Bhakta, John M Miller. (2007) Pharmacologic targets for atrial fibrillation. Expert Opinion on Therapeutic Targets 11:9, 1161-1178
CrossRef130
Nora Goldschlager, Andrew E. Epstein, Gerald V. Naccarelli, Brian Olshansky, Bramah Singh, Harold R. Collard, Elizabeth Murphy. (2007) A Practical Guide for Clinicians Who Treat Patients with Amiodarone: 2007. Heart Rhythm 4:9, 1250-1259
CrossRef131
S. Geidel, M. Lass, C. Schneider, F. Jensen, K. Hassan, S. Boczor, K.-H. Kuck, J. Ostermeyer. (2007) Risikofaktoren für ein Rezidiv von permanentem Vorhofflimmern nach kombinierter Mitralklappen- und Ablationschirurgie. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 21:4, 156-162
CrossRef132
Aman Chugh. (2007) Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation. Expert Review of Cardiovascular Therapy 5:4, 663-672
CrossRef133
SHEETAL CHANDHOK, DAVID SCHWARTZMAN. (2007) Amiodarone Therapy for Atrial Rhythm Control: Insights Gained From a Single Center Experience. Journal of Cardiovascular Electrophysiology 18:7, 714-718
CrossRef134
Emile G Daoud. (2007) Percutaneous catheter ablation of atrial fibrillation. Expert Review of Cardiovascular Therapy 5:4, 693-705
CrossRef135
Paulus Kirchhof, Günter Breithardt. (2007) New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation. Heart Rhythm 4:6, 790-793
CrossRef136
William Cahoon, Maureen P. Flattery, Michael L. Hess. (2007) Amiodarone: Development, Clinical Indications, and Safety. Progress in Cardiovascular Nursing 22:3, 173-176
CrossRef137
David Conen, Ludovic Melly, Christoph Kaufmann, Stefan Bilz, Peter Ammann, Beat Schaer, Christian Sticherling, Beat Muller, Stefan Osswald. (2007) Amiodarone-Induced Thyrotoxicosis. Journal of the American College of Cardiology 49:24, 2350-2355
CrossRef138
Chang Sheng Ma, Xu Liu, Fu Li Hu, Jian Zeng Dong, Xing Peng Liu, Xin Hua Wang, De Yong Long, Ri Bo Tang, Rong Hui Yu, Chun Shan Lu, Dong Ping Fang, Peng Hao, Xiao Hui Liu. (2007) Catheter ablation of atrial fibrillation in patients with hyperthyroidism. Journal of Interventional Cardiac Electrophysiology 18:2, 137-142
CrossRef139
Samuel Lévy. (2007) Do we need pharmacological therapy for atrial fibrillation in the ablation era?. Journal of Interventional Cardiac Electrophysiology 17:3, 189-194
CrossRef140
David Fedida. (2007) Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opinion on Investigational Drugs 16:4, 519-532
CrossRef141
Zimetbaum, Peter, . (2007) Amiodarone for Atrial Fibrillation. New England Journal of Medicine 356:9, 935-941
Full Text142
D J Bradley, W-K Shen. (2007) Overview of Management of Atrial Fibrillation in Symptomatic Elderly Patients: Pharmacologic Therapy Versus AV Node Ablation. Clinical Pharmacology & Therapeutics 81:2, 284-287
CrossRef143
Yaariv Khaykin. (2007) Cost-effectiveness of catheter ablation for atrial fibrillation. Current Opinion in Cardiology 22:1, 11-17
CrossRef144
Kohei Miyaji, Hiroshi Tada, Kengo Fukushima Kusano, Tohru Hashimoto, Kenichi Kaseno, Shigeki Hiramatsu, Kazuyoshi Tadokoro, Shigeto Naito, Kazufumi Nakamura, Shigeru Oshima, Koichi Taniguchi, Tohru Ohe. (2007) Efficacy and Safety of the Additional Bepridil Treatment in Patients With Atrial Fibrillation Refractory to Class I Antiarrhythmic Drugs. Circulation Journal 71:8, 1250-1257
CrossRef145
Yoshifusa Aizawa, Hiroshi Furushima, Hiroshi Watanabe. (2007) Atrial Fibrillation Revisited-With a Special Reference to Primary Prevention-. Journal of Arrhythmia 23:1, 4-11
CrossRef146
Carlo Pappone, Giuseppe Augello, Simone Sala, Filippo Gugliotta, Gabriele Vicedomini, Simone Gulletta, Gabriele Paglino, Patrizio Mazzone, Nicoleta Sora, Isabelle Greiss, Andreina Santagostino, Laura LiVolsi, Nicola Pappone, Andrea Radinovic, Francesco Manguso, Vincenzo Santinelli. (2006) A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation. Journal of the American College of Cardiology 48:11, 2340-2347
CrossRef147
Anthony N. Lucas, Mehmet Tanol, Michelle P. McIntosh, Roger A. Rajewski. (2006) Preparation and Purification of Desethylamiodarone Hydrochloride. Synthetic Communications 36:22, 3371-3376
CrossRef148
Ángel M. Martínez-Brotóns, Ricardo Ruiz-Granell, Salvador Morell, Eva Plancha, Ángel Ferrero, Araceli Roselló, Ángel Llácer, Roberto García-Civera. (2006) Rendimiento terapéutico de un protocolo prospectivo de cardioversión en la fibrilación auricular persistente. Revista Española de Cardiología 59:10, 1038-1046
CrossRef149
M. G. Hennersdorf, B. E. Strauer. (2006) Vorhofflimmern. Der Internist 47:10, 990-1000
CrossRef150
D. Steven, B. Lutomsky, T. Rostock, S. Willems. (2006) Moderne Pharmakotherapie bei supraventrikulären und ventrikulären Herzrhythmusstörungen. Der Internist 47:10, 1013-1023
CrossRef151
Brian R. Triola, Peter R. Kowey. (2006) Antiarrhythmic drug therapy. Current Treatment Options in Cardiovascular Medicine 8:5, 362-370
CrossRef152
ERIC N. PRYSTOWSKY. (2006) Assessment of Rhythm and Rate Control in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 17:s2, S7-S10
CrossRef153
Todd Rudo, Peter Kowey. (2006) Atrial fibrillation: Choosing an antiarrhythmic drug. Current Cardiology Reports 8:5, 370-376
CrossRef154
Simone Musco, Jonathan Seltzer, Peter R Kowey. (2006) Future directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiology 2:5, 545-553
CrossRef155
Bramah N. Singh. (2006) Amiodarone: A multifaceted antiarrhythmic drug. Current Cardiology Reports 8:5, 349-355
CrossRef156
Valentin Fuster, Lars E. Rydén, David S. Cannom, Harry J. Crijns, Anne B. Curtis, Kenneth A. Ellenbogen, Jonathan L. Halperin, Jean-Yves Le Heuzey, G. Neal Kay, James E. Lowe, S. Bertil Olsson, Eric N. Prystowsky, Juan Luis Tamargo, Samuel Wann. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology 48:4, e149-e246
CrossRef157
Rodney H. Falk. (2006) Atrial Fibrillation or Sinus Rhythm?. Journal of the American College of Cardiology 48:4, 731-733
CrossRef158
Ahmad Hersi, L. Brent Mitchell, D. George Wyse. (2006) Atrial fibrillation: Challenges and opportunities. Canadian Journal of Cardiology 22, 21C-26C
CrossRef159
Eduard Shantsila, Timothy Watson, Gregory YH Lip. (2006) Therapy for atrial fibrillation: new challenges. Therapy 3:4, 445-448
CrossRef160
U. Ravens, E. Wettwer, U. Schotten, R. Weßel, D. Dobrev. (2006) Neue Antiarrhythmika in der Therapie des Vorhofflimmerns. Herzschrittmachertherapie & Elektrophysiologie 17:2, 64-72
CrossRef161
Panos E Vardas, Eleftherios M Kallergis. (2006) Drug therapy for atrial fibrillation. Expert Opinion on Pharmacotherapy 7:9, 1121-1131
CrossRef162
K. P. O’Rourke, C. Cotter, D. Mullane, P. Thorpe, P. Sullivan. (2006) The outcome of Direct Current Cardioversion (DCC) for the treatment of Atrial Fibrillation (AF) in a district general hospital in Ireland. Irish Journal of Medical Science 175:2, 41-45
CrossRef163
Lee A. Biblo, Johan Aasbo. (2006) To catch a moving target. Heart Rhythm 3:6, 638-639
CrossRef164
C. Burgess, A. Blaikie, T. Ingham, G. Robinson, S. Narasimhan. (2006) Monitoring the use of amiodarone: compliance with guidelines. Internal Medicine Journal 36:5, 289-293
CrossRef165
JAN W. SCHRICKEL, JOERG O. SCHWAB, ALEXANDER YANG, ALEXANDER BITZEN, BERNDT LUDERITZ, THORSTEN LEWALTER. (2006) "Torsade de Pointes" in Patients with Structural Heart Disease and Atrial Fibrillation Treated with Amiodarone, beta-Blockers, and Digitalis. Pacing and Clinical Electrophysiology 29:4, 363-366
CrossRef166
Keiichi Ashikaga, Takao Kobayashi, Masaomi Kimura, Shingen Owada, Shingo Sasaki, Atsushi Iwasa, Ken-ichi Furukawa, Shigeru Motomura, Ken Okumura. (2006) Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. European Journal of Pharmacology 536:1-2, 148-153
CrossRef167
Vincent E. Hagens, Dirk J. Van Veldhuisen, Harry J. G. M. Crijns, Isabelle C. Van Gelder. (2006) Implication from Randomized Trials of Rate and Rhythm Controls on Management of Patients with Persistent Atrial Fibrillation. Annals of Noninvasive Electrocardiology 11:2, 170-186
CrossRef168
KATSUMI MATSUMOTO, TOSHIYUKI ISHIKAWA, SHINICHI SUMITA, KOHEI MATSUSHITA, NORIKO INOUE, TSUKASA KOBAYASHI, KAZUAKI UCHINO, KAZUO KIMURA, SATOSHI UMEMURA. (2006) Assessment of Atrial Regional Wall Motion Using Strain Doppler Imaging During Biatrial Pacing in the Bradycardia-Tachycardia Syndrome. Pacing and Clinical Electrophysiology 29:3, 220-225
CrossRef169
Usha B. Tedrow, William G. Stevenson. 2006. Management of Ventricular Arrhythmias in Heart Failure. , 183-202.
CrossRef170
Aamir Cheema, Hugh Calkins. 2006. Atrial Arrhythmia. , 167-182.
CrossRef171
RIYAKO SHIBATA, KOJIRO NAKAO, SATOKI FUKAE, KIYOTAKA MATSUO, KATSUSUKE YANO. (2006) Angiotensin-Converting Enzyme Inhibitor Suppresses the Incidence of Prolonged and Fractionated Right Atrial Electrograms. Pacing and Clinical Electrophysiology 29:2, 164-170
CrossRef172
T. Lewalter, G. Nickenig. (2006) Pharmakotherapie der supraventrikulären Rhythmusstörungen. Der Internist 47:1, 80-88
CrossRef173
Amit Vora. (2006) Management of atrial fibrillation in rheumatic valvular heart disease. Current Opinion in Cardiology 21:1, 47-50
CrossRef174
2006. Amiodarone. , 148-173.
CrossRef175
AKIRA FUJIKI. (2006) Nihon Naika Gakkai Zasshi 95:2, 253-260
CrossRef176
Marcello Disertori, Roberto Latini, Aldo Pietro Maggioni, Pietro Delise, Giuseppe Di Pasquale, Maria Grazia Franzosi, Lidia Staszewsky, Gianni Tognoni. (2006) Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. Journal of Cardiovascular Medicine 7:1, 29-38
CrossRef177
Masayuki Yasuda, Yuji Nakazato, Akitoshi Sasaki, Yasunobu Kawano, Kaoru Nakazato, Takashi Tokano, Hiroyuki Daida. (2006) Clinical Evaluation of Adverse Effects During Bepridil Administration for Atrial Fibrillation and Flutter. Circulation Journal 70:6, 662-666
CrossRef178
Richard L. Page, Dan M. Roden. (2005) Drug therapy for atrial fibrillation: where do we go from here?. Nature Reviews Drug Discovery 4:11, 899-910
CrossRef179
Gemma Pelargonio, Eric N Prystowsky. (2005) Rate versus rhythm control in the management of patients with atrial fibrillation. Nature Clinical Practice Cardiovascular Medicine 2:10, 514-521
CrossRef180
Marco Budeus, Marcus Hennersdorf, Christian Perings, Heinrich Wieneke, Raimund Erbel, Stefan Sack. (2005) Prediction of the Recurrence of Atrial Fibrillation After Successful Cardioversion with P Wave Signal-Averaged ECG. Annals of Noninvasive Electrocardiology 10:4, 414-419
CrossRef181
Sven Kathofer, Dierk Thomas, Christoph A. Karle. (2005) The Novel Antiarrhythmic Drug Dronedarone: Comparison with Amiodarone. Cardiovascular Drug Reviews 23:3, 217-230
CrossRef182
Brian Olshansky. (2005) Rate versus rhythm control strategies for AF. Current Treatment Options in Cardiovascular Medicine 7:5, 371-381
CrossRef183
Peter R. Kowey, Mathias L. Stoenescu. (2005) Selection of Drugs in Pursuit of a Rhythm Control Strategy. Progress in Cardiovascular Diseases 48:2, 139-145
CrossRef184
Hector F. Lozano, Cesar A. Conde, Todd Florin, Gervasio A. Lamas. (2005) Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2:9, 1000-1007
CrossRef185
Akiko Shiroshita-Takeshita, Bianca J. J. M. Brundel, Stanley Nattel. (2005) Atrial Fibrillation: Basic Mechanisms, Remodeling and Triggers. Journal of Interventional Cardiac Electrophysiology 13:3, 181-193
CrossRef186
(2005) Amiodarone versus Sotalol for Atrial Fibrillation. New England Journal of Medicine 353:6, 627-630
Full Text187
Singh, Bramah N., Singh, Steven N., Reda, Domenic J., Tang, X. Charlene, Lopez, Becky, Harris, Crystal L., Fletcher, Ross D., Sharma, Satish C., Atwood, J. Edwin, Jacobson, Alan K., Lewis, H. Daniel Jr., Raisch, Dennis W., Ezekowitz, Michael D., . (2005) Amiodarone versus Sotalol for Atrial Fibrillation. New England Journal of Medicine 352:18, 1861-1872
Full Text188
Redi Pecini, Hanne Elming, Ole Dyg Pedersen, Christian Torp-Pedersen. (2005) New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opinion on Emerging Drugs 10:2, 311-322
CrossRef189
Abraham G. Kocheril, Hugh Calkins, Arjun D. Sharma, Daniel Cher, Harrison A. Stubbs, Jon E. Block. (2005) Hybrid Therapy with Right Atrial Catheter Ablation and Previously Ineffective Antiarrhythmic Drugs for the Management of Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology 12:3, 189-197
CrossRef190
Heather M. Ross, Dusan Z. Kocovic, Peter R. Kowey. (2005) Pharmacologic Therapies for Atrial Fibrillation. The American Journal of Geriatric Cardiology 14:2, 62-67
CrossRef191
B John Hynes, Jerry C Luck, Deborah L Wolbrette, Mazhar Khan, Gerald V Naccarelli. (2005) A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone. Future Cardiology 1:2, 135-144
CrossRef192
Marcio Lerch Stürmer, Mario Talajic, Bernard Thibault, Peter G. Guerra, Marc Dubuc, Paul Novak, Denis Roy. (2005) Management of Atrial Fibrillation in Patients With Congestive Heart Failure. The American Journal of Geriatric Cardiology 14:2, 91-94
CrossRef193
Ashish Agarwal, Meghan York, Bharat K. Kantharia, Michael Ezekowitz. (2005) Atrial Fibrillation: Modern Concepts and Management. Annual Review of Medicine 56:1, 475-494
CrossRef194
Alexandra E. R??tz Bravo, Juergen Drewe, Raymond G. Schlienger, Stephan Kr??henb??hl, Hans Pargger, Wolfgang Ummenhofer. (2005) Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature*. Critical Care Medicine 33:1, 128-134
CrossRef195
Yasuo Okumura, Ichiro Watanabe, Toshiko Nakai, Hidezou Sugimura, Kenichi Hashimoto, Riko Masaki, Kimie Ohkubo, Yasuhiro Takagi, Atsushi Shindo, Yukio Ozawa, Satoshi Saito, Katsuo Kanmatsuse. (2005) Recurrence of Atrial Fibrillation After Internal Cardioversion of Persistent Atrial Fibrillation. Circulation Journal 69:12, 1514-1520
CrossRef196
Katsumi Matsumoto, Toshiyuki Ishikawa, Shinichi Sumita, Kohei Matsushita, Noriko Kawasaki, Tsukasa Kobayashi, Kazuaki Uchino, Kazuo Kimura, Satoshi Umemura. (2005) Beneficial Effects of Biatrial Pacing on Cardiac Function in Patients With Bradycardia - Tachycardia Syndrome. Circulation Journal 69:7, 831-836
CrossRef197
Kaoru Sugi, Mahito Noro, Takao Sakata, Naoki Tezuka, Takeshi Nakae, Kenta Kumagai, Tsuyoshi Sakai, Ayaka Numata, Hidetoshi Itakura, Akiyoshi Moriyama, Shingo Kujime. (2005) Pharmacological Treatment for Atrial Fibrillation. Journal of Arrhythmia 21:3, 358-370
CrossRef198
Yuji Nakazato, Masayuki Yasuda, Akitoshi Sasaki, Youji Iida, Yasunobu Kawano, Kaoru Nakazato, Takashi Tokano, Yoriaki Mineda, Masataka Sumiyoshi, Yasuro Nakata, Hiroyuki Daida. (2005) Conversion and Maintenance of Sinus Rhythm by Bepridil in Patients With Persistent Atrial Fibrillation. Circulation Journal 69:1, 44-48
CrossRef199
J. R. Ehrlich, S. H. Hohnloser. (2005) Medikament
se Kardioversion von Vorhofflimmern. Zeitschrift f
CrossRef200
Hsu, Li-Fern, Jaïs, Pierre, Sanders, Prashanthan, Garrigue, Stéphane, Hocini, Mélèze, Sacher, Fréderic, Takahashi, Yoshihide, Rotter, Martin, Pasquié, Jean-Luc, Scavée, Christophe, Bordachar, Pierre, Clémenty, Jacques, Haïssaguerre, Michel, . (2004) Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure. New England Journal of Medicine 351:23, 2373-2383
Full Text201
Page, Richard L., . (2004) Newly Diagnosed Atrial Fibrillation. New England Journal of Medicine 351:23, 2408-2416
Full Text202
Robert M. Lobel, Daniel L. Lustgarten. (2004) Treatment of arrhythmias in patients with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 6:6, 519-529
CrossRef203
VIDAL ESSEBAG, TOM HADJIS, ROBERT W. PLATT, MICHAL ABRAHAMOWICZ, LOUISE PILOTE. (2004) Effect of Amiodarone Dose on the Risk of Permanent Pacemaker Insertion. Pacing and Clinical Electrophysiology 27:11, 1519-1525
CrossRef204
Hanne Elming, Bente Brendorp, Steen Pehrson, Ole Dyg Pedersen, Lars Køber, Christian Torp-Petersen. (2004) A benefit–risk assessment of class III antiarrhythmic agents. Expert Opinion on Drug Safety 3:6, 559-577
CrossRef205
Stephan Geidel, Michael Lass, Sigrid Boczor, Karl-Heinz Kuck, Jörg Ostermeyer. (2004) Monopolar and Bipolar Radiofrequency Ablation Surgery: 3-Year Experience in 90 Patients with Permanent Atrial Fibrillation. The Heart Surgery Forum 7:5, E398-E402
CrossRef206
Anirban Choudhury, Gregory YH Lip. (2004) New antiarrhythmic agents for atrial fibrillation. Therapy 1:1, 111-121
CrossRef207
Daniela Husser, Martin Stridh, Leif Sornmo, Pyotr Platonov, S. Bertil Olsson, Andreas Bollmann. (2004) Analysis of the Surface Electrocardiogram for Monitoring and Predicting Antiarrhythmic Drug Effects in Atrial Fibrillation. Cardiovascular Drugs and Therapy 18:5, 377-386
CrossRef208
TOSHIYUKI OSAKA, MASATOSHI YAMAZAKI, ERIKO YOKOYAMA, ATSUSHI ITO, ITSUO KODAMA. (2004) Sotalol Reverses Remodeled Action Potential in Patients with Chronic Atrial Fibrillation but Does Not Prevent Arrhythmia Recurrence. Journal of Cardiovascular Electrophysiology 15:8, 877-884
CrossRef209
G Nichol, E Huszti, J Rokosh, A Dumbrell, J McGowan, L Becker. (2004) Impact of informed consent requirements on cardiac arrest research in the United States: exception from consent or from research?. Resuscitation 62:1, 3-23
CrossRef210
Anirban Choudhury, Gregory YH Lip. (2004) Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. Expert Opinion on Investigational Drugs 13:7, 841-855
CrossRef211
Mazhar H. Khan. (2004) Oral class III antiarrhythmics: what is new?. Current Opinion in Cardiology 19:1, 47-51
CrossRef212
Takashi Komatsu, Shin Nakamura, Osamu Suzuki, Daisuke Horiuchi, Kunihiko Yomogida, Ken Okumura. (2004) Long-Term Prognosis of Patients With Paroxysmal Atrial Fibrillation Depends on Their Response to Antiarrhythmic Therapy. Circulation Journal 68:8, 729-733
CrossRef213
Marleen E. Irwin. (2004) Cardiac Pacing Device Therapy for Atrial Dysrhythmias. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 15:3, 377-390
CrossRef214
GERALD V. NACCARELLI, B. JOHN HYNES, DEBORAH L. WOLBRETTE, LUNA BHATTA, MAZHAR KHAN, SORAYA SAMII, JERRY C. LUCK. (2003) Atrial Fibrillation in Heart Failure:. Prognostic Significance and Management. Journal of Cardiovascular Electrophysiology 14:s12, S281-S286
CrossRef215
DOUGLAS L. PACKER, SAM ASIRVATHAM, THOMAS M. MUNGER. (2003) Progress in Nonpharmacologic Therapy of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 14:s12, S296-S309
CrossRef216
C.J. Boos. (2003) Rate or rhythm control in persistent atrial fibrillation?. QJM 96:12, 881-892
CrossRef217
Ole Dyg Pedersen, Bente Brendorp, Lars Køber, Christian Torp-Pedersen. (2003) Prevalence, Prognostic Significance, and Treatment of Atrial Fibrillation in Congestive Heart Failure With Particular Reference to the DIAMOND-CHF Study. Congestive Heart Failure 9:6, 333-340
CrossRef218
Gajanan S. Joshi, James C. Burnett. 2003. Cardiovascular Agents. .
CrossRef219
R. Wong, W. Cheung, J. R. Stockigt, D. J. Topliss. (2003) Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. Internal Medicine Journal 33:9-10, 420-426
CrossRef220
Parimal B. Maniar, Jonathan S. Steinberg. (2003) Evolving concepts in the treatment of atrial fibrillation. Current Cardiology Reports 5:5, 358-363
CrossRef221
Mark D Carlson, John Ip, John Messenger, Scott Beau, Steven Kalbfleisch, Pierre Gervais, Douglas A Cameron, Aurelio Duran, Jesus Val-Mejias, Judith Mackall, Michael Gold. (2003) A new pacemaker algorithm for the treatment of atrial fibrillation. Journal of the American College of Cardiology 42:4, 627-633
CrossRef222
Carlo Pappone, Salvatore Rosanio, Giuseppe Augello, Giuseppe Gallus, Gabriele Vicedomini, Patrizio Mazzone, Simone Gulletta, Filippo Gugliotta, Alessia Pappone, Vincenzo Santinelli, Valter Tortoriello, Simone Sala, Alberto Zangrillo, Giuseppe Crescenzi, Stefano Benussi, Ottavio Alfieri. (2003) Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. Journal of the American College of Cardiology 42:2, 185-197
CrossRef223
Paul Dorian, Iqwal Mangat. (2003) Restoring sinus rhythm in atrial fibrillation. Journal of the American College of Cardiology 42:1, 30-32
CrossRef224
(2003) Maintenance of sinus rhythm in patients with atrial fibrillation. Journal of the American College of Cardiology 42:1, 20-29
CrossRef225
GERIAN C. GRONEFELD, STEFAN H. HOHNLOSER. (2003) beta-Blocker Therapy in Atrial Fibrillation. Pacing and Clinical Electrophysiology 26:7p2, 1607-1612
CrossRef226
BRADLEY P. KNIGHT. (2003) Atrial Fibrillation in Patients with Congestive Heart Failure. Pacing and Clinical Electrophysiology 26:7p2, 1620-1623
CrossRef227
ANTONIO PACIFICO, PHILIP D. HENRY. (2003) Class I or Class III Agents for Atrial Fibrillation:. Are We Asking the Right Question?. Pacing and Clinical Electrophysiology 26:7p2, 1613-1619
CrossRef228
J.örg Carlsson, Sinisa Miketic, J.ürgen Windeler, Alessandro Cuneo, Sebastian Haun, Stefan Micus, Sabine Walter, Ulrich Tebbe. (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. Journal of the American College of Cardiology 41:10, 1690-1696
CrossRef229
Simon P. Fynn, Derick M. Todd, W. Julian, C. Hobbs, Karen L. Armstrong, P. Fitzpatrick, Clifford J. Garratt. (2003) Effect of Amiodarone on Dispersion of Atrial Refractoriness and Cycle Length in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 14:5, 485-491
CrossRef230
Cabot, Richard C.Harris, Nancy Lee, McNeely, William F., Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Malhotra, Atul, Muse, Victorine V., Mark, Eugene J., . (2003) Case 12-2003. New England Journal of Medicine 348:16, 1574-1585
Full Text231
Jan Nemec, Win-Kuang Shen. (2003) Antiarrhythmic drugs: new agents and evolving concepts. Expert Opinion on Investigational Drugs 12:3, 435-453
CrossRef232
Kristin E. Ellison, William G. Stevenson, Michael O. Sweeney, Laurence M. Epstein, William H. Maisel. (2003) Management of Arrhythmias in Heart Failure. Congestive Heart Failure 9:2, 91-99
CrossRef233
Jean-Marie Jouannic, Sophie Delahaye, Laurent Fermont, J
CrossRef234
Corey M. Slovis, Peter J. Kudenchuk, Marvin A. Wayne, Richard Aghababian, Edgardo J. Rivera-Rivera. (2003) P REHOSPITAL M ANAGEMENT OF A CUTE T ACHYARRHYTHMIAS. Prehospital Emergency Care 7:1, 2-12
CrossRef235
Linda Josephson, Maureen McMullen. (2003) Atrial fibrillation: Beyond “irregularly irregular”. Nursing Management (Springhouse) 34, 4-6
CrossRef236
Bradley R Williams, Jiwon Kim. (2003) Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations. Drugs & Aging 20:6, 445-463
CrossRef237
Philip R. Liebson. (2003) ALLHAT and AFFIRM. Preventive Cardiology 6:1, 54-60
CrossRef238
Vidal Essebag, Tom Hadjis, Robert W Platt, Louise Pilote. (2003) Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. Journal of the American College of Cardiology 41:2, 249-254
CrossRef239
Knut Gjesdal. (2003) Editorial: Cardioversion of persistent atrial fibrillation—not yet an outdated treatment. Scandinavian Cardiovascular Journal 37:6, 307-308
CrossRef240
Falk, Rodney H., . (2002) Management of Atrial Fibrillation — Radical Reform or Modest Modification?. New England Journal of Medicine 347:23, 1883-1884
Full Text241
Uma Srivatsa, Nitin Wadhani, Bramah N. Singh. (2002) Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm. Current Cardiology Reports 4:5, 401-410
CrossRef242
Eduardo B. Saad, Nassir F. Marrouche, Andrea Natale. (2002) Ablation of atrial fibrillation. Current Cardiology Reports 4:5, 379-387
CrossRef243
Linda Josephson, Maureen McMullen. (2002) Atrial Fibrillation. Dimensions of Critical Care Nursing 21:5, 180-189
CrossRef244
Sanjeev Saksena, Atul Prakash, Paul Ziegler, John D Hummel, Paul Friedman, Vance J Plumb, D.George Wyse, Eric Johnson, Stephanie Fitts, Rahul Mehra. (2002) Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. Journal of the American College of Cardiology 40:6, 1140-1150
CrossRef245
Magdi Sami. (2002) Are we ready for dual-site right atrial pacing?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 40:6, 1151-1152
CrossRef246
&NA;. (2002) Symptomatic atrial fibrillation: management depends on the pattern presented. Drugs & Therapy Perspectives 18:7, 10-13
CrossRef247
W. S. Aronow. (2002) Management of the Older Person With Atrial Fibrillation. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:6, M352-M363
CrossRef248
Wei Sun, Jonnalagedda S. M. Sarma, Bramah N. Singh. (2002) Chronic and Acute Effects of Dronedarone on the Action Potential of Rabbit Atrial Muscle Preparations: Comparison With Amiodarone. Journal of Cardiovascular Pharmacology 39:5, 677-684
CrossRef249
Wilbert S. Aronow. (2002) Atrial Fibrillation. Heart Disease91-101
CrossRef250
Nicholas S Peters, Richard J Schilling, Prapa Kanagaratnam, Vias Markides. (2002) Atrial fibrillation: strategies to control, combat, and cure. The Lancet 359:9306, 593-603
CrossRef251
Volker K??hlkamp, Ralph Bosch, Christian Mewis, Ludger Seipel. (2002) Use of ??-Blockers in Atrial Fibrillation. American Journal of Cardiovascular Drugs 2:1, 37-42
CrossRef252
Hirotsugu Atarashi, Hiroshi Inoue, Masatake Fukunami, Kaoru Sugi, Chikuma Hamada, Hideki Origasa, for the Sinus Rhythm Maintenance in, Randomized Trial (SMART) Investigat. (2002) Double-Blind Placebo-Controlled Trial of Aprindine and Digoxin for the Prevention of Symptomatic Atrial Fibrillation. Circulation Journal 66:6, 553-553
CrossRef253
Bente Brendorp, Oledyg Pedersen, Christian Torp-Pedersen, Naji Sahebzadah, Lars K??ber. (2002) A Benefit-Risk Assessment of Class III Antiarrhythmic Agents. Drug Safety 25:12, 847-865
CrossRef254
Stanley Nattel, Paul Khairy, Denis Roy, Bernard Thibault, Peter Guerra, Mario Talajic, Marc Dubuc. (2002) New Approaches to Atrial Fibrillation Management. Drugs 62:16, 2377-2397
CrossRef255
Guy Chatap, Karine Giraud, Jean-Pierre Vincent. (2002) Atrial Fibrillation in the Elderly. Drugs & Aging 19:11, 819-846
CrossRef256
Tsuyoshi Shiga, Michi Wakaumi, Taku Imai, Tsuyoshi Suzuki, Fumitaka Hosaka, Yuichiro Yamada, Naoki Matsuda, Morio Shoda, Ryo Sugiura, Nobuhisa Hagiwara, Hiroshi Kasanuki. (2002) Effect of Low-Dose Amiodarone on Atrial Fibrillation or Flutter in Japanese Patients With Heart Failure. Circulation Journal 66:6, 600-600
CrossRef257
G. Muqtada Chaudhry, Charles I. Haffajee. (2002) Algorithms useful in the treatment of atrial fibrillation. Current Opinion in Cardiology 17:1, 52-57
CrossRef258
WILLIAM G. STEVENSON, KRISTIN E. ELLISON, MICHAEL O. SWEENEY, LAURENCE M. EPSTEIN, WILLIAM H. MAISEL. (2002) Management of Arrhythmias in Heart Failure. Cardiology in Review 10:1, 8-14
CrossRef259
James P. Tsikouris, Craig D. Cox. (2001) A Review of Class III Antiarrhythmic Agents for Atrial Fibrillation: Maintenance of Normal Sinus Rhythm. Pharmacotherapy 21:12, 1514-1529
CrossRef260
Sheila A Doggrell. (2001) Amiodarone - waxed and waned and waxed again. Expert Opinion on Pharmacotherapy 2:11, 1877-1890
CrossRef261
Stephen B. Sloan, Howard H. Weitz. (2001) POSTOPERATIVE ARRHYTHMIAS AND CONDUCTION DISORDERS. Medical Clinics of North America 85:5, 1171-1189
CrossRef262
Jayant Bagai, Boaz Avitall. (2001) Atrial fibrillation. Current Treatment Options in Cardiovascular Medicine 3:4, 261-276
CrossRef263
Ashok Garg, Gregory K. Feld. (2001) Atrial flutter. Current Treatment Options in Cardiovascular Medicine 3:4, 277-289
CrossRef264
Falk, Rodney H., . (2001) Atrial Fibrillation. New England Journal of Medicine 344:14, 1067-1078
Full Text265
Frank Pelosi, Fred Morady. (2001) Evaluation and Management of Atrial Fibrillation. Medical Clinics of North America 85:2, 225-244
CrossRef266
. (2001) Amiodaron tegen recidief atriumfibrilleren. Medisch-Farmaceutische Mededelingen 39:3, 52-52
CrossRef267
MARK D. CARLSON. (2001) How to Manage Atrial Fibrillation: An Update on Recent Clinical Trials. Cardiology in Review 9:2, 60-69
CrossRef268
Rosemary S. Bubien, Javier E. Sanchez. (2001) Atrial Fibrillation: Treatment Rationale and Clinical Utility of Nonpharmacologic Therapies. AACN Clinical Issues: Advanced Practice in Acute & Critical Care 12:1, 140-155
CrossRef269
Hideo Konagai, Junichi Nitta, Akihiro Niwa, Yasuhiro Satoh, Akihiko Nogami, Kazutaka Aonuma, Yoshito Iesaka, Michiaki Hiroe, Fumiaki Marumo. (2001) Clinical Characteristics of Rapid Atrial Fibrillation Preceding Ventricular Tachycardia. Japanese Circulation Journal 65:12, 1022-1028
CrossRef270
Kevin S. Channer. (2001) Current Management of Symptomatic Atrial Fibrillation. Drugs 61:10, 1425-1437
CrossRef271
Eric Guillemare, Aline Marion, Dino Nisato, Patrick Gautier. (2000) Inhibitory Effects of Dronedarone on Muscarinic K+ Current in Guinea Pig Atrial Cells. Journal of Cardiovascular Pharmacology 36:6, 802-805
CrossRef272
Stefan H Hohnloser, Karl-Heinz Kuck, Jurgen Lilienthal. (2000) Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. The Lancet 356:9244, 1789-1794
CrossRef273
G. Muqtada Chaudhry, Charles I. Haffajee. (2000) Antiarrhythmic agents and proarrhythmia. Critical Care Medicine 28:Supplement, N158-N164
CrossRef274
Mark P. Teng, Edward Catherwood, Daniel P. Melby. (2000) Cost Effectiveness of Therapies for Atrial Fibrillation. PharmacoEconomics 18:4, 317-333
CrossRef275
(2000) Amiodarone to Prevent Recurrence of Atrial Fibrillation. New England Journal of Medicine 343:8, 578-580
Full Text
- Letters
